

Bulletin from the annual general meeting of CellaVision AB (publ)

The following resolutions were passed at the annual general meeting (the "AGM") of CellaVision AB (publ) ("CellaVision") on 29 April 2021. Due to the covid-19 pandemic, CellaVision's annual general meeting was carried out through advance voting (postal voting) only.

Adoption of income statement and balance sheet and discharge from liability

The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the board of directors and the managing director were discharged from liability for the financial year 2020.

Allocation of profit or loss

The AGM resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021.

Board of Directors and auditor

The AGM resolved, in accordance with the nomination committee's proposal, on re-election of Mikael Worning, Anna Malm Bernsten, Christer Fåhraeus, Åsa Hedin, Niklas Prager, Jürgen Riedl and Stefan Wolf as board members. Mikael Worning was also elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Deloitte AB as auditor.

The AGM further resolved in accordance with the nomination committee's proposal on remuneration to the Board of Directors, remuneration for committee work and that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination committee for the next annual general meeting

The AGM resolved, in accordance with the nomination committee's proposal, that the same principles for appointing the nomination committee that were resolved upon at the AGM of 2020 shall also apply for the AGM of 2022.

Remuneration report

The AGM approved the Board of Directors' remuneration report for 2020.

Amendment of the articles of association

The AGM resolved, in accordance with the Board of Directors' proposal, to amend the articles of association.

Contact

Maria Morin
VP HR & Corporate Communications
Direct: +46 (0) 46 460 16 52
Mobile: +46 (0) 709 92 62 28

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

[Bulletin from the annual general meeting of CellaVision AB \(publ\)](#)